Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors

Inclusion Criteria: * Age 18 to 75 years at the time of informed consent. * Histologically or cytologically confirmed advanced or metastatic solid tumor with documented TROP2 expression (per local testing or central confirmation). * Disease progression on, intolerance to, or ineligibility for available standard therapy. * At least one measurable lesion per RECIST 1.1. * ECOG performance status 0 to 1. * Adequate organ function (hematologic, renal, hepatic) within protocol-defined limits. * Life expectancy ≥ 12 weeks. * Willingness to use effective contraception during study participation and for a protocol-defined period after last infusion (if of childbearing potential). * Ability to understand and willingness to sign written informed consent. Exclusion Criteria: * Active central nervous system (CNS) metastases or leptomeningeal disease (unless treated and clinically stable for ≥ 4 weeks). * Prior allogeneic hematopoietic stem cell transplant or solid organ transplant. * Uncontrolled active infection, including uncontrolled hepatitis B, hepatitis C, or HIV infection. * Active autoimmune disease requiring systemic immunosuppression. * Clinically significant cardiovascular disease (e.g., recent myocardial infarction or stroke within 6 months, uncontrolled arrhythmia). * Receipt of another investigational agent within 2 weeks (or 5 half-lives, whichever is longer) prior to lymphodepleting chemotherapy. * Prior gene-modified cellular therapy within 3 months prior to enrollmen…